|Home | About | Journals | Submit | Contact Us | Français|
Non-allelic homologous recombination (NAHR) between segmental duplications in proximal chromosome 15q breakpoint (BP) regions can lead to microdeletions and microduplications. Several individuals with deletions flanked by BP3 and BP4 on 15q13, immediately distal to, and not including the Prader–Willi/Angelman syndrome (PW/AS) critical region and proximal to the BP4–BP5 15q13.3 microdeletion syndrome region, have been reported; however, because the deletion has also been found in normal relatives, the significance of these alterations is unclear. We have identified six individuals with deletions limited to the BP3–BP4 interval and an additional four individuals with deletions of the BP3–BP5 interval from 34046 samples submitted for clinical testing by microarray-based comparative genomic hybridization (aCGH). Of four individuals with BP3–BP4 deletions for whom parental testing was conducted, two were apparently de novo and two were maternally inherited. A comparison of clinical features, available for five individuals in our study (four with deletions within BP3–BP4 and one with a BP3-BP5 deletion), with those in the literature show common features of short stature and/or failure to thrive, microcephaly, hypotonia, and premature breast development in some individuals. Although the BP3–BP4 deletion does not yet demonstrate statistically significant enrichment in abnormal populations compared with control populations, the presence of common clinical features among probands and the presence of genes with roles in development and nervous system function in the deletion region suggest that this deletion may have a role in abnormal phenotypes in some individuals.
Segmental duplications (SDs) on proximal chromosome 15q mediate non-allelic homologous recombination (NAHR), resulting in deletion or duplication of the intervening material. Such recombination events result in Prader–Willi/Angelman syndrome (PW/AS), autism, and a recently described 15q13.3 microdeletion syndrome.1, 2 The segmental duplications are grouped into breakpoints (BPs) on the basis of where breaks recur in these various genomic disorders. BP1 and BP2 are proximal to the PW/AS critical region and are the locations of the proximal BPs of class I and II deletions of the region, respectively. BP3 is the location of the distal BPs of the common PW/AS deletions.3 There are multiple additional clusters of SDs distal to BP3, two of which, BP4 and BP5, are commonly involved in the formation of supernumerary chromosomes from the region and are involved in the 15q13.3 microdeletion syndrome.2, 4, 5, 6 Few deletions in 15q13 with the proximal break in BP3 have been reported. Deletions of the material between BP3 and BP4 have been thought to have minimal phenotypic effect based on inheritance patterns and phenotypes of similar severity among individuals with deletions spanning BP3–BP5 and those limited to the BP4–BP5 interval.2, 7, 8, 9 In this study, we report clinical details of five individuals with deletions that encompass the BP3–BP4 interval and compare them with cases in the literature to clarify the role this microdeletion may have in the development of an abnormal phenotype.
From May 2004 to August 2009, we tested 34046 probands' samples submitted to Signature Genomic Laboratories. The most common clinical presentations were mental retardation, developmental delay, or multiple congenital anomalies. For individuals with 15q13 microdeletions described here, consent was obtained to publish photographs.
Microarray-based comparative genomic hybridization (aCGH) was performed on 24380 of the probands' samples with a bacterial artificial chromosome (BAC) microarray (the SignatureChip; Signature Genomic Laboratories, Spokane, WA, USA).10 There have been multiple versions of the SignatureChip, with increasing genomic coverage in successive versions, and all versions have had coverage in the BP3–BP4 region on 15q13.1q13.2. Microarray analysis was performed as described.10, 11
The remaining 9666 probands were tested by oligonucleotide-based aCGH with either a 105K-feature (SignatureChip Oligo Solution, custom designed by Signature Genomic Laboratories, made by Agilent Technologies, Santa Clara, CA, USA) or a 135-K feature (SignatureChip Oligo Solution version 2.0, custom designed by Signature Genomic Laboratories, made by Roche NimbleGen, Madison, WI, USA) whole-genome array using previously described methods.12, 13 Samples from eight of the nine individuals with deletions encompassing the BP3–BP4 interval detected on BAC array were reanalyzed with the 105K-feature microarray. Samples from subject 8, whose deletion was initially detected by BAC array, and from subject 7, who had no previous BAC array analysis, were analyzed with the 135-K feature microarray. Results were displayed using custom aCGH analysis software (Genoglyphix; Signature Genomic Laboratories).
All deletions encompassing the BP3–BP4 interval reported here were visualized by metaphase fluorescence in situ hybridization (FISH) using BAC clone RP11-408F10, as previously described.14 Parental samples, when available, were also assayed with metaphase FISH.
During the study period, we identified 10 individuals with deletions encompassing the interval between BP3 and BP4 on 15q13 that did not extend proximally into the PW/AS commonly deleted region. Five of the subjects had deletions flanked by BP3 proximally and BP4 distally, four subjects had deletions flanked by BP3 proximally and BP5 distally, and subject 4 had an atypical deletion with the proximal BP in the interval between BP3 and BP4 and the distal BP within BP4 (chr15:27, 359, 655-28801860, UCSC March 2006 hg18 build) (Figure 1). Inheritance of the deletions was determined through parental FISH in seven cases: two BP3–BP4 deletions were apparently de novo, and two were maternally inherited; two BP3–BP5 deletions were apparently de novo, and one was maternally inherited; in the remaining three cases parents were unavailable for testing.
Clinical features of five of the subjects in our cohort and those in the literature are summarized in Table 1.
Subject 1 presented with dysmorphic features and borderline intellectual function and was found to have a maternally inherited BP3–BP4 deletion. Birth weight was 3.03kg (10th percentile), length was 45.7cm (<3rd percentile), and occipitofrontal circumference (OFC) was 34.5cm (50th percentile). He had growth deficiency as an infant, with height and weight below the third percentile at 7.5 months (64.3cm and 6.21kg), whereas OFC was normal (45.5cm, 75th percentile). Examination at 7.5 months showed a large anterior fontanel (4 × 8cm), dysmorphic features, pectus excavatum, and hypotonia. He developed seizures at 18 months, which continued until the age of 4 years. A head CT scan at 18 months was normal. Testing at the age of 6 years using the Wechsler Intelligence Scale for Children showed an overall IQ of 71. At 13 years and 10 months of age, his height was 157cm, weight was 46.6kg, and OFC was 56.5cm. He had speech apraxia and difficulty with pronunciation. He was dysmorphic (Figure 2, Table 1), hyperopic, and had amblyopia and accommodative esotropia. The subject's mother, who also has the deletion, is healthy, of normal height, and has normal developmental and cognitive abilities. The family history is significant for a maternal half brother and two maternal first cousins with learning disabilities, and a paternal uncle with porencephaly and mental retardation. Further maternal family members were not available for testing.
Subject 2 presented with developmental delay and hypotonia and was found to have an apparently de novo BP3–BP4 deletion. She had mild delays in acquiring skills, although physical therapy was discontinued at 3 years of age. Speech was also mildly delayed, but she had an extensive vocabulary at 4 years of age. She was not toilet trained and had occasional temper tantrums, but showed no significant behavioral problems. Hypotonia noted at 2 years of age was resolved by 4 years. Ophthalmological examination showed asymmetrical optic nerve cupping, which was considered to be a normal variant. At 4 years and 5 months of age, her height was 100cm, weight was 14.7kg, and OFC was 47cm. She was non-dysmorphic.
Subject 3 presented with developmental delay, congenital heart defect, hypotonia, ataxic gait, and dysmorphic features and was found to have a maternally inherited BP3–BP4 deletion. Birth weight was 1.03kg (75–90th percentile). He had a complex congenital heart defect, with obstruction of the left pulmonary veins, anomalous drainage of the right pulmonary veins into a scimitar vein leading to the inferior vena cava, and atrial and ventricular septal defects. He had bilateral cryptorchidia and inguinal hernias that required surgical correction. He had severe gastroesophageal reflux and required G-tube placement at 1 year of age, which he continued to use up to 6 years. He had hypogammaglobulinemia and frequent viral infections. Brain MRI at 21 months of age showed moderate dilatation of the lateral and third ventricles and prominent extra-axial CSF spaces. At 11.5 months, he had some head control, was able to roll over at 21 months, crawled by 3 years, and walked independently by 4 years. At 6 years of age, he had an ataxic gait, was not yet toilet trained, spoke simple sentences with a limited vocabulary, and had significant articulation problems. He had a disrupted sleep pattern, requiring melatonin for induction of sleep. He failed to thrive in early childhood, and at 2.5 years of age his weight was at the 3rd percentile and height at the 25th percentile. However, by 6 years of age his weight and height were at the 50th percentile. His physical examination showed a large head (OFC of 54cm, 2 SD above the mean) and mild dysmorphic features (Figure 2, Table 1). He had significant hypotonia with hyperextensible joints. The subject's mother, who also has the deletion, is healthy and non-dysmorphic, and has normal developmental and cognitive abilities.
Subject 4 presented with developmental delays, hypotonia, seizures, and growth delay and was found to have an atypical 15q13.1q13.2 deletion that involves part of the BP3–BP4 region. Birth weight was 3.26kg (25–50th percentile) and length was 50.8cm (50–75th percentile). Neonatally, she had rotary nystagmus and severe hypotonia. Subsequently, she had slow growth and feeding difficulties. Seizures have been lifelong, starting within the first months of life. Head MRI and EEG were normal. Strabismus was treated with surgery and glasses. She held her head erect at 16 months, first walked with the assistance of a walker at 3.5 years, and only said ‘mama' and ‘dada' at 6 years and 9 months. She had food aversions and a history of constipation. At the age of 6 years and 9 months, her height was 96cm, weight was 15.9kg, and OFC was 48.5cm. She had dysmorphic features (Figure 2, Table 1), severe hypotonia, and muscle weakness. She is adopted; the biological mother had vision problems and strabismus, and no information was available about the biological father.
Subject 5 presented with developmental delays and microcephaly and was found to have an apparently de novo BP3–BP5 deletion. Birth weight was 2.98kg (10–25th percentile). Neonatal complications included meconium staining of the amniotic fluid, natal teeth, a heart murmur, and hypoglycemia. A newborn screen showed high serum immunoreactive trypsinogen (IRT) levels. The subject's maternal grandmother had cystic fibrosis (CF); preconceptional gene testing in the subject's mother revealed that she was a CF carrier (ΔF508), whereas her father was negative for a panel of 70 mutations. Therefore, the subject had sweat testing, which was normal, and did not have CFTR mutational analysis. No CF symptoms were present, and she was considered to be a CF carrier. She rolled at 10 months, crawled at 14 months, cruised at 16 months, and spoke some sentences by 3 years. She showed a poor attention span, flapped her hands when excited, and had difficulty following directions; developmental preschool and therapies helped with these behaviors. She had poor growth initially and was at or below the third percentile from 6 to 26 months. Microcephaly has been persistent, and a head MRI at 2 years showed periventricular leukomalacia with volume loss within the parietooccipital regions, posterior thinning of the corpus callosum, and prominent extra-axial fluid in the posterior fossa, likely a mega cisterna magna. At the age of 4 years and 2 months, her height was 97cm, weight was 15.5kg, and OFC was 45.7cm. She had dysmorphic features (Table 1) and developed bilateral breast buds by 16 months of age. Her parents have normal head sizes.
We report clinical details of five individuals with deletions encompassing the BP3–BP4 interval on 15q13. These deletions can be de novo or inherited from clinically normal parents, and a comparison of these cases with each other and with those in the literature shows some phenotypic similarities. On the basis of these phenotypic similarities and gene content of the region, we propose that deletions of the BP3–BP4 interval can contribute to an abnormal phenotype. However, there is still phenotypic variability among subjects, and a consistent and recognizable phenotype is not present. This finding is similar to other recently described CNVs that have been associated with a wide spectrum of phenotypes ranging from severely affected to asymptomatic individuals, such as microdeletions of proximal 1q21.1 and TAR syndrome,15 microdeletions and microduplications of distal 1q21.1,16, 17 microdeletions of 15q13.37, 18, 19, 20, 21 and microdeletions and microduplications of 16p11.2.22, 23, 24 One proposed explanation for the variable phenotypes is that the microdeletion or microduplication is primarily responsible for the disease, but other modifiers, genetic and environmental, will ultimately influence the phenotypic presentation.25 An alternative hypothesis is that these loci are the modifiers for other yet-to-be-identified mutations in the genome. Variability in these other factors among individuals with the same microdeletion may explain their varying phenotypes. With this new understanding, closer scrutiny and broader interpretations are called for when examining novel genomic rearrangements that may be inherited from an apparently normal parent.
Previous reports have suggested that the deletions flanked by BP3 and BP4 are benign because they have been identified in healthy relatives of probands but not in all affected relatives (Table 1).2, 7, 9 Van Bon et al7 described individuals with deletions flanked by BP3 and BP5 to be similarly affected as those with deletions flanked by BP4 and BP5, and suggested that deletion of the BP3–BP4 interval did not contribute to the phenotype. However, a comparison of our subjects with those in the literature with deletions within the BP3–BP5 interval shows some common phenotypic features that may be attributable to the deletion of genes in the BP3–BP4 interval (Table 2). Some features are only present among individuals with deletions of the BP3–BP4 interval, such as hearing loss (2/7 among BP3–BP4 deletions vs 0/38 among BP4–BP5 deletions). Other features, although not exclusively found in individuals with deletions including the BP3–BP4 interval, are more prevalent among these individuals, including failure to thrive (4/6 vs 4/38), short stature (4/7 vs 4/42), microcephaly (4/7 vs 4/44), hypotonia (5/6 vs 13/27), renal abnormalities (1/7 vs 1/38), and premature puberty or abnormally early breast development (1/7 vs 1/38). Among individuals with BP3–BP4 or BP3–BP5 deletions, premature or abnormal breast development was seen in two females and in a male as precocious puberty and gynecomastia (Table 1), whereas a single individual with a deletion limited to BP4–BP5 has been reported with early pubarche.2 Although a majority (5/6) of the individuals with deletions limited to BP3–BP4 have eye abnormalities, both structural and movement disorders, with five probands specifically reporting issues ranging from coloboma to nystagmus and strabismus, a similar variety of abnormalities has also been reported in individuals with deletions limited to BP4–BP5.2, 7, 18, 21 Conversely, some features are more common among individuals with BP4–BP5 deletions, including behavioral concerns (36/50 among BP4–BP5 deletions vs 0/6 among BP3–BP4 deletions), macrocephaly (9/44 vs 1/7), and spinal abnormalities (1/38 vs 0/7), suggesting that genes in this region are contributing to the findings. Overall, the finding of phenotypic similarities among individuals with deletions incorporating the BP3–BP4 interval that are distinct from the BP4–BP5 deletion phenotype suggests that deletions of the BP3–BP4 interval may contribute to an abnormal phenotype in some individuals.
Haploinsufficiency of the four genes that lie in the ~1.1-Mb interval between BP3 and BP4 on 15q13.1 may explain the abnormal phenotypes seen in individuals with BP3–BP4 deletions. Although subject 4 is not haploinsufficient for all of these genes, other unidentified factors may be affecting her phenotype, especially given its relative severity in comparison with other subjects; therefore, all genes within the recurrently deleted interval should be critically assessed. Amyloid beta A4 precursor protein-binding family A, member 2 (APBA2, OMIM 602712; also known as MINT2 or X11L) plays a role in nervous system development and is expressed only in neuronal tissue, encoding a neuronal adapter protein shown to interact with synaptic vesicle proteins and to regulate neurite outgrowth.26, 27 Homozygous knockout mice have monoamine imbalances in the forebrain and impaired conflict resolution.28 Apba2 also interacts with amyloid precursor protein and suppresses its amyloidogenic cleavage.29 Tight junction protein 1 (TJP1, OMIM 601009) encodes zonula occludens-1, a scaffolding protein involved in regulation of cell growth in a cell density-dependent manner and in stabilizing tight junctions and connecting them to the cytoskeleton.30 Tjp1 has ubiquitous expression during development, with some later specialization in the CNS, eye, and heart.31 Knockout mice are embryonic lethal, although the heterozygous knockouts are reportedly normal.32 Deletion of APBA2 or TJP1 could affect development, particularly of the nervous system. Necdin-like gene 2 (NDNL2, OMIM 608243) is ubiquitously expressed in high levels in testes33 and encodes part of the SMC5-6 protein complex that is responsible for resolution of DNA recombination.34 Little is known about the fourth gene in the region, FAM189A1, although it likely encodes a transmembrane protein expressed in brain, eye, kidney, testes, and uterus (UniGene, http://www.ncbi.nlm.nih.gov/unigene).
In addition to deletion of the genes between BP3 and BP4, genes within BPs may also be disrupted or deleted in these individuals. Within BP4 is CHRFAM7A, which is a fusion of exons E-A of FAM7A (several copies of which are also in BP4) to exons 5–10 and the 3' untranslated region of CHRNA7, which lies at the distal end of the BP4–BP5 region and extends into BP5.35 Although the function of FAM7A is unknown, CHRNA7 encodes the α7 subunit of the nicotinic cholinergic receptor that is hypothesized to contribute to the seizures and developmental delay seen in some individuals with 15q13.3 microdeletions extending to BP5.2, 20, 36 CHRFAM7A may be deleted in individuals with BP3–BP4 deletions, is likely to be deleted in subject 4, and is deleted in individuals with BP3–BP5 deletions. Studies have suggested an association between a 2-bp deletion polymorphism of CHRFAM7A, which disrupts the reading frame of the gene, and schizophrenia and dementia.37, 38 However, it is unclear whether this gene's transcript is translated, and homozygous deletions of CHRFAM7A have been found in normal individuals.39 Therefore, a deletion of this gene may not always cause an abnormal phenotype; however, as suggested by the association between psychosis and lower CHRFAM7A copy number, a deletion of the gene could predispose to neurocognitive disorders.39
A comparison of the frequency of a deletion or duplication among cases with the frequency in controls is one method used to determine whether a genetic alteration predisposes individuals to an abnormal phenotype. No BP3–BP4 deletions were found in three control groups consisting of 2493 individuals,40 2026 individuals,41 and 3651 individuals (Evan Eichler, unpublished data), whereas another study with a control group of 2792 individuals did find one BP3–BP4 deletion.42 Combining these controls gives a similar frequency of deletions in cases referred for aCGH testing, and in controls (6/34046 cases that do not encompass the BP4–BP5 region vs 1/10962 controls, two-tailed P=0.86, χ2 with Yates' correction). The Database of Genomic Variants has a single entry with a deletion of the region, found in a cohort of 506 healthy northern German individuals and 270 HapMap individuals.43 Given that the frequency of these cases is rare (~1/5700) in our population of individuals undergoing aCGH testing, a larger control set is needed for a more statistically powerful comparison.
Compared to other rearrangements of proximal 15q, BP3–BP4 deletions are relatively rare. In contrast to the 9/34046 (0.03%) individuals with deletions extending distally from BP3, our laboratory has detected 54 individuals with BP4–BP5 deletions out of 18517 individuals tested (0.29%), a 10-fold higher frequency. This difference is likely in part due to the genomic architecture of the region. Proximal 15q is polymorphic, with inversions and deletions found within the BPs, and inversions of segments between BPs,1, 2, 35, 44, 45 such as the inversion that is enriched in mothers of children with Angelman syndrome.46 Some configurations of the region will be more likely to predispose to deletion following NAHR, when homologous SDs are in direct orientation with each other.45 It has been estimated that out of ~45% of chromosomes 15 have within BP4 relative to the reference human genome that puts an ~300kb SD in direct orientation with a homologous SD in BP5, NAHR between which would lead to a BP4–BP5 deletion.44, 45 In contrast, BP3 has much smaller segments of high homology to BP4 and BP5 (around 30kb), and many segments on BP3 have less homology to the corresponding segments in BP4 or BP5 than the homology between those segments in BP4 and BP5.1, 2 There is, on average, ~94% sequence identity between BP3 and BP4/BP5, compared with ~97% sequence identity between BP4 and BP5.2 BP3 has much larger segments of homology with BP1 and BP2, which explains why almost all chromosomal deletions causing PW/AS are flanked by BP3.1 Larger control cohorts are necessary to determine whether the relative infrequency of BP3–BP4 deletions in our study population may be attributed to genomic architecture or to the absence of a clinically recognizable phenotype.
Individuals with deletions of the BP3–BP4 interval have common clinical features, including short stature or failure to thrive, microcephaly, hypotonia, and premature breast development in some individuals. BP3–BP4 deletions may be present in unaffected relatives, and two deletions have been reported in control cohorts, suggesting that additional factors have a role in the development of an abnormal phenotype. Although current comparison with control populations does not demonstrate statistically significant enrichment of the BP3–BP4 deletion in abnormal individuals, the phenotypic similarities and gene content suggest that this deletion contributes to an abnormal phenotype in some individuals. Larger control cohorts and additional reports of individuals with BP3–BP4 deletions will further help to clarify the role that these deletions have in the development of abnormal phenotypes.
We thank Aaron Theisen (Signature Genomic Laboratories) for his critical reading of the manuscript.
Jill A Rosenfeld, Justine Coppinger, Blake C. Ballif, Roger Schultz, Beth Torchia, Trilochan Sahoo, Bassem Bejjani, and Lisa G Shaffer are employees of Signature Genomic Laboratories, a subsidiary of Perkin-Elmer. The remaining authors declare no conflict of interest.